designer491 / iStockphoto.com
23 January 2018Americas
Celgene reveals plans to acquire Juno for $9bn
Celgene and Juno Therapeutics announced yesterday that they have entered into a deal that will see Celgene acquire Juno.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019 Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.
Editor's picks
Editor's picks
Americas
2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019 Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.
Americas
2 February 2018 Seattle Genetics has announced that it will acquire biotech company Cascadian Therapeutics for approximately $614 million.
Asia-Pacific
12 February 2018 Allergan is set to acquire Australia-based Elastagen, a clinical-stage company focused on developing medical device products based on recombinant tropoelastin, for $95 million.
Americas
31 January 2019 Global biopharmaceutical company Celgene has signed a collaboration deal worth up to nearly $1 billion to develop a preclinical therapeutic for the treatment of blood cancers, including leukaemia.